Developing continuous systemic delivery of endostatin has been a goal of many laboratories. We have employed a method of gene therapy utilizing different viral constructs. Here, we report that a new serotype of adeno-associated viruses, which incorporates canine endostatin, provides dose-dependent transgene expression in the circulation after intramuscular injection in mice. Elevated levels of endostatin remained stable in the circulation for at least 4 months. In vitro assays determined that the protein expressed was biologically active. Antitumor activities of the above construct demonstrated a U-shape curve, where the maximum activity was observed within a certain critical concentration range. These data suggest that an optimum dose range may be required to achieve therapeutic efficacy in large animal models.
Introduction
Angiogenesis, the sprouting of new capillaries from preexisting vascular beds, is critical for many pathological disorders, such as tumor growth, development and metastasis. 1 An extensive network of stimulators and inhibitors regulates angiogenesis, and the net balance between these positive and negative regulators determines the angiogenic phenotype. [2] [3] [4] Antiangiogenic therapies have therefore been used to target the tumor vascular system in cancer therapy due to their high degree of specificity for endothelial cells, 3 low toxicity 2 and relative lack of acquired drug resistance. 5 Endostatin is a 20 kDa COOH-terminal proteolytic fragment of collagen type XVIII, first isolated from murine hemangioendothelioma cell conditioned media as an antiangiogenic agent capable of inhibiting tumor growth without displaying toxic side effects. 3, [6] [7] [8] Endostatin inhibits phosphorylation of focal adhesion kinase via binding to a5b1 integrin. 9 Cell surface glypicans have also been shown to be low-affinity endostatin receptors. 10 Endostatin has been implicated in several signaling pathways, such as downregulation of c-myc, 11 RhoA activity 12 and cyclin-D1, 13 blockage of VEGF signaling, 14, 15 and inhibition of the wnt-signaling pathway. 16 Furthermore, endostatin has been shown to bind and inactivate metalloproteinases [17] [18] [19] and to regulate a spectrum of genes that suppress angiogenesis. 20 Recently, we have shown that an NH 2 -terminal 27-aminoacid synthetic peptide of endostatin, corresponding to the zinc-binding domain, is responsible for its antitumor properties. 21 Gene therapy is a feasible approach to combat cancer, with a sustained systemic therapeutic release of antiangiogenic substances and a highly localized delivery. Sustained elevated blood levels obtained by continuous administration from an implanted pump have been demonstrated to be significantly more effective against tumors in animals than intermittent peak levels from bolus dosing. 7 There are now many studies demonstrating the efficacy of antiangiogenic gene therapy in tumorbearing animal models. Adenoviruses are the most commonly used vectors for this strategy. [22] [23] [24] [25] [26] [27] [28] [29] However, expression of antiangiogenic molecules mediated by adenovirus-based vectors is limited by an effective host immune response and transient nature of expression. Adeno-associated virus (AAV)-based vectors are emerging as potential alternative vectors for cancer therapy because AAV is a non-pathogenic vector with limited host immune response, and allows for long-term and stable transgene expression. Furthermore, the inhibition of tumor growth was possible using AAV-based vectors expressing appropriate levels of endostatin. [30] [31] [32] [33] [34] Initially, we set out to treat spontaneous tumors in canines using AAV-mediated canine FcEndostatin (cFcES). Canines develop spontaneous tumors and serve as a suitable model for human cancer. There are several advantages of using Fc-encoded endostatin: (1) the halflife is longer; (2) higher expression is obtained; and (3) the purification process is facilitated. Furthermore, human and murine FcEndostatin have been successfully used in tumor inhibition studies. 35 Among 11 serotypes of AAV isolated, AAV serotype 1 (AAV-1) has the most potential transduction in muscle than other serotypes. Therefore, in this study we tested the efficacy of AAV-1/cFcES transduction on muscles in SCID mice before initiating canine clinical trials. We show that AAV-1-mediated cFcES gene therapy offers efficient and systemic therapeutic release of cFcES for human pancreatic tumor inhibition in SCID mice, and that optimum dosing follows a biphasic curve that is U-shaped.
Materials and methods

Cell culture and reagents
Human pancreatic adenocarcinoma BxPC-3 cells, which are p53 À/À , were grown and maintained as described previously. 2, 7 Human umbilical cord endothelial cells (HUVEC; Clonetics, Walkersville, MD) were cultured in endothelial cell growth medium (EGM-2; Clonetics). BxPC-3 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD).
Purified rat anti-mouse CD31 (PECAM) was obtained from BD PharMingen (San Diego, CA). Rabbit anticanine endostatin antibodies were produced by immunizing rabbits with recombinant canine endostatin. Animals were exsanguinated after four immunizations.
Cloning of canine endostatin
Canine endostatin was cloned from a canine liver cDNA library (Clontech, Palo Alto, CA) using degenerate PCR primers based on known human and murine endostatin DNA sequences. Forward primer (5 0 -GCAGATGACA TCCTGGCCA-3 0 ) and reverse primer (5 0 -TGGCTCAT CTTYGTGG-3 0 ) were synthesized by GIBCO BRL (Gaithersburg, MD). The reaction was allowed to denature at 941C for 1 min, anneal at 551C for 1 min, and polymerize at 721C for 1.5 min for 40 cycles using QIAGEN Taq polymerase (QIAGEN, Valencia, CA) and Q buffer.
The canine immunoglobin Fcg chain was fused at the N-terminus of canine endostatin to make cFcES. This construct was inserted into the pdCs expression vector, 36 where cFcES is under the control of human cytomegalovirus (CMV) enhancer and promoter.
Construction and purification of adeno-associated viruses pTR/canine FcES was constructed by inserting cFcES DNA fragment into the region of green fluorescence protein (GFP) in the plasmid pTRUF. 37 Recombinant AAV vectors were produced, purified and titered as described previously. 38 ELISA determination of canine FcEndostatin Serum samples were obtained every 2 weeks by retroorbital puncture with non-heparinized capillary tubes (Fisher, Pittsburgh, PA) after anesthesia. Samples were placed at 41C overnight and serum was collected after centrifugation at 10 000 r.p.m. for 10 min. Canine FcEndostatin concentrations were determined by competition ELISA (Cytimmune Sciences, College Park, MD) following the manufacturer's protocol. Final endostatin concentration was determined by taking the average of the last time points that showed maximum expression.
Western blot determination of canine FcEndostatin expression Serum from infected mice was collected as described above and analyzed by Western blot for canine endostatin. A detailed description of this procedure was given previously. 39 Serum samples (100 ml) of AAV-1/cFcESand AAV-1/GFP-infected mice were compared with different concentrations of recombinant cFcES. The immunoblot was probed with rabbit anti-canine endostatin antibody (1:2000) . Development was carried out with goat anti-rabbit IgG-horseradish peroxidase secondary antibody (Sigma, St Louis, MO, 1:1000) and chemiluminescence (Pierce, Rockford, IL).
Matrigel tube formation assay
Tube formation assay using HUVEC cells was performed as described previously. 39 Serum samples (250 ml) of AAV-1/cFcES-and AAV-1/GFP-infected mice were used and compared to recombinant cFcES (10 mg/ml).
Animal studies
All animal procedures were performed in compliance with Boston Children's Hospital guidelines, and protocols were approved by the Institutional Animal Care and Use Committee. Male (6-8 weeks) SCID mice (Massachusetts General Hospital, Boston, MA) were used. Animals were anesthetized via inhalation of isoflurane (Baxter, Deerfield, IL) before all surgical procedures and observed until fully recovered. Animals were euthanized by a lethal dose of CO 2 asphyxiation.
Tumor model and adeno-associated virus injections
Human pancreatic BxPC-3 tumor cells were implanted as described previously. 7 Tumors were measured every 3-5 days in two diameters with a dial caliper. Volumes were determined using the formula (Width) 2 Â Length Â 0.52. Data are represented as volume of treated tumor over control (T/C).
Mice were infected with the indicated particles intramuscularly (i.m.). BxPC-3 cells were implanted into infected mice at 45 days post-infection.
Immunohistochemistry
Tumors were fixed in 10% buffered formalin overnight at 41C. The next day, tumors were washed three times in PBS and paraffin-embedded. Sections (5 mm) were permeabilized with 40 mg/ml proteinase K (Roche Diagnostics Corp., Indianapolis, IN) in 0.2 M Tris-HCl buffer (pH 7.6) for 25 min at 371C, and washed with PBS, and then incubated with PECAM (1:250) overnight at 41C. Stainings were amplified using tyramide signal amplification direct and indirect kits (NEN Life Science Products Inc., Boston, MA). Sections were photographed at Â 200 magnification using a NIKON TE300 microscope (Melville, NY). Vessel density (average of three fields) was determined by IPLab software.
Statistical methods
Data are expressed as mean7s.d. Statistical significance was assessed by analysis of variance (ANOVA) with a significant overall F-test followed by treatment comparisons relative to AAV-1/GFP control by Dunnett's posthoc tests in order to protect against Type I errors due to multiple pairwise group comparisons against a single control. 40 Two-tailed Po0.05 was considered statistically significant. Statistical analysis was performed using the SPSS software package (version 14.0, SPSS Inc., Chicago, IL).
Results
Cloning of canine endostatin
Canine endostatin was cloned from a canine liver cDNA library using degenerate primers based on conserved DNA sequences obtained from human and murine endostatin. Amino-acid comparison showed that canine endostatin is 84.8 and 83.7% identical to human and murine endostatin, respectively ( Figure 1 ). Furthermore, all three histidines (at positions 1, 3 and 11) and aspartic acid (at position 76) residues important for Zn binding are conserved. 41 Dose-dependent expression of endostatin We and others have determined that, among the new serotypes of AAV, AAV-1 has better transduction efficiency in muscle. 42, 43 Therefore, AAV-1/cFcES vectors were produced in which cFcES is under the control of the human CMV enhancer and promoter (Figure 2a) . Before initiating canine clinical trials, we evaluated the efficacy of the AAV-1/cFcES construct in SCID mice.
Different doses of AAV-1/cFcES particles were injected i.m. into SCID mice ( Figure 2b ). As control, AAV-1/GFP vector was used (5.5 Â 10 11 particles). Peak levels of cFcES were reached at approximately 8 weeks postinfection and were stable up to the end of the experiment (15 weeks). Different serum levels of endostatin were observed, with the highest level of B4225 ng/ml (2 Â 10 12 particles of AAV-1/cFcES) and the lowest level of B19 ng/ml (AAV-1/GFP and 4 Â 10 9 particles of AAV-1/ cFcES). There was an excellent correlation between serum levels and the doses of AAV-1/cFcES particles injected (Pearson r ¼ 0.9977; Figure 2c ). These data suggest that stable and different endostatin levels could be achieved by injecting different doses of AAV-1/cFcES.
Characterization of biological activity of adenoassociated virus-1-produced canine FcEndostatin
To determine the biological activity of AAV-1-produced cFcES from mouse serum, first cFcES expression was analyzed by Western blot to identify the non-degraded protein (Figure 3a) . The cFcES expression in sera from mice infected with AAV-1/cFcES (2 Â 10 12 particles, n ¼ 2) for 15 weeks was compared to that in sera from a mouse with AAV-1/GFP and different concentrations of purified recombinant cFcES protein. No detectable cFcES was observed from serum of the AAV-1/GFPinfected mouse, whereas serum samples from the AAV-1/ cFcES-infected mice revealed a protein of size similar to (Figure 3a ). This analysis shows that the cFcES protein secreted from muscles transduced with AAV-1 vectors is not degraded.
To test the biological activity of the AAV-1-produced cFcES, Matrigel tube formation assay was performed. Sera from the AAV-1/cFcES-and AAV-1/GFPinfected mice (15 weeks) were tested and compared to purified recombinant cFcES for their ability to inhibit HUVEC tube formation (Figure 3b ). The number of branch points/cm 2 were significantly lower for recombinant cFcES (Po0.001) and AAV-1/cFcES (Po0.001) treatments compared to AAV-1/GFP control (Figure 3c ).
These data show that recombinant cFcES could inhibit HUVEC tube formation and suggest that the AAV-1-produced cFcES is biologically active.
Systemic inhibition of human pancreatic cancer by adeno-associated virus-1/canine FcEndostatin follows a biphasic dose curve To determine the optimal endostatin serum level for human pancreatic cancer inhibition, pancreatic BxPC-3 tumor cells (5 Â 10 6 ) were injected s.c. into dorsa of the AAV-1-infected mice 45 days after infection. Tumor growth was followed up for 59 days and measurements Endostatin's U-shaped antitumor activity RM Tjin Tham Sjin et al were taken every 3-4 days. Human pancreatic cancer was inhibited by B33% (P ¼ 0.03) only in mice infected with 4 Â 10 10 AAV-1/cFcES particles, whereas doses higher or lower had no effect (Figure 4a ). At the completion of the experiment, pancreatic BxPC-3 tumors were excised (Figure 4b ) from the mice and tumor volumes were determined by weight. Human pancreatic cancer was inhibited by B32% (P ¼ 0.03; Figure 4b ) only at serum levels of approximately 126 ng/ml, when tumor volumes (based on weight) were plotted against serum cFcES levels. This is comparable to the data from the earlier measurements (see Figure 4a) . When cFcES serum levels were higher or lower than 126 ng/ml, antitumor efficacy was lower. A slight tumor inhibition was observed for a serum level of 1040 ng/ml (B11%, P ¼ NS). However, this inhibition was not statistically significant. These data indicate that there is a U-shaped response of human pancreatic tumor growth to endostatin concentrations, and that the optimal endostatin level for tumor growth inhibition is approximately 126 ng/ml in SCID mice.
Antiangiogenic effect of adeno-associated virus-1/canine FcEndostatin
We also determined the antiangiogenic effect of AAV-1/ cFcES treatment. Therefore, pancreatic cancers treated with AAV-1/cFcES and AAV-1/GFP were analyzed for vessel density (CD31) (Figure 5a and b) . Human pancreatic tumor sections from day 59 were formalin fixed and paraffin embedded and then stained with CD31 antibodies. There were no significant differences in %CD31/hpf between serum level groups compared to AAV-1/GFP (all P40.80) except for 126 ng/ml level (P ¼ 0.02, Figure 5b ). These data further corroborate the U-shaped tumor response to endostatin that was observed in the previous experiment (see Figure 4) .
Optimal endostatin serum level for human pancreatic cancer inhibition is between 126 and 173 ng/ml To determine more precisely the optimal endostatin serum levels for human pancreatic tumor inhibition, 1 Â 10 11 , 2 Â 10 10 and 1 Â 10 10 AAV-1/cFcES particles were injected i.m. into SCID mice (Figure 6a ). Stable and long-term cFcES expression (175 ng/ml) was observed in mice injected with 1 Â 10 11 AAV-1/cFcES particles beginning at 7 weeks post-infection (Figure 6a ). For 2 Â 10 10 and 1 Â 10 10 AAV-1/cFcES particles, stable and long-term cFcES expression was observed between 8-10 weeks (Figure 6a) , with maximum expressions of 50 and 32 ng/ml respectively. Human pancreatic BxPC-3 tumor cells (5 Â 10 6 ) were injected s.c. into the infected mice 45 days after infection to determine the effect on tumor inhibition. Pancreatic tumor growth was inhibited by 31% (P ¼ 0.02) at serum cFcES levels of 175 ng/ml compared to AAV-1/GFP (Figure 6b ). Serum levels of 32 ng/ml (P ¼ 0.99) and 50 ng/ml (P ¼ 0.43) were not significantly different than AAV-1/GFP (Figure 6b) .
Treatment of human pancreatic cancer with 175 ng/ml AAV-1/cFcES reduced vessel density by 73% (P ¼ 0.009) compared to AAV-1/GFP (3 ng/ml), while the remaining doses of 32 (P ¼ 0.99) and 50 ng/ml (P ¼ 0.82) had no effect (Figure 6c) . These results combined with prior data suggest that the optimal endostatin serum level for pancreatic cancer inhibition is between 126 and 175 ng/ml, while levels higher or lower did not inhibit growth of pancreatic cancer (Figure 7 ).
Discussion
We have previously shown that continuous delivery of endostatin obtained by an implanted osmotic pump is 10-fold more effective in inhibiting pancreatic tumor growth than daily bolus injections. 7 Therefore, antiangiogenic gene therapy is a feasible approach to obtain sustained systemic therapeutic release of angiogenesis inhibitors. An added benefit of antiangiogenic gene therapy is that it may reduce the cost of injecting recombinant protein on a daily basis. Furthermore, the use of AAV vectors is advantageous because of the relative lack of vector-associated toxicity and immunity Endostatin's U-shaped antitumor activity RM Tjin Tham Sjin et al with sustained long-term transgene expression. Here, we have shown that an AAV-1 vector can provide stable, systemic and long-term expression of cFcES. SCID mice are not entirely devoid of an immune response. Therefore, we examined the production of antibodies against cFcES in serum from 15-weeks-infected mice. No antibodies were detected at any of the infected doses (data not shown).
An optimum dose range of endostatin was required for effective pancreatic tumor growth inhibition. Canine FcEndostatin serum levels of 126-175 ng/ml demonstrated significant inhibition of pancreatic tumor growth. No inhibition was observed at higher or lower serum levels, suggesting that a U-shaped curve seems to be associated with the antitumor activity of endostatin as a function of protein concentration (see Figure 7) . Similar results were observed for recombinant human endostatin using the human pancreatic BxPC-3 and ASPC-1 tumor models, where the more aggressive ASPC-1 tumor required more endostatin for effective treatment, thereby shifting the endostatin U-shaped response. 44 These results show that the U-shaped endostatin response will be tumor-dependent and is not restricted to the endostatin range of 126-175 ng/ml. It is highly likely that more angiogenic (aggressive) tumors will require a higher endostatin range for effective treatment, while the reverse is true for less angiogenic tumors. Also, using a colon liver metastasis model, Chen et al. 24 showed that blood endostatin levels for optimal survival were between 200 and 300 ng/ml, while levels higher or lower had a reduced survival rate.
24 Similar U-shaped responses have been reported for other antiangiogenic treatments, such as angiostatin, 45 interferon-a 46 and rosiglitazone, 47 where a low dose was more effective than a high dose. Therefore, it is possible that a U-shaped response curve is not uncommon for antiangiogenic therapies. Thus, determination of optimum endostatin concentration may be an important factor for long-term tumor treatment.
Several groups have reported that at high serum endostatin levels no or insignificant tumor inhibition was observed. Employing adenoviral-mediated expression of endostatin, it was shown that at high endostatin serum levels of 15-20 mg/ml, no T241 fibrosarcoma and BxPC3 pancreatic tumor inhibition was observed. 25 Similarly, Endostatin's U-shaped antitumor activity RM Tjin Tham Sjin et al
Pawliuk et al. 48 reported that systemic endostatin levels of 750 ng/ml failed to inhibit T241 fibrosarcoma delivered through retroviral endostatin-transduced HSCs. Here, we have also shown that no pancreatic tumor inhibition was observed at high concentrations of endostatin (see Figure 4 ). It is possible that receptor desensitization (such as integrins) occurs at sustained high serum endostatin levels, which would impair endostatin activity in vivo. Also, it has been reported that sustained high levels of adenoviral endostatin elicit toxicity and immunogenicity. Wen et al. 28 have shown that high-dose intravenous delivery of adenoviral endostatin was associated with severe acute toxicity. However, no adenoviral-mediated endostatin toxicity was observed by other groups. Besides toxicity, potential immunogenicity against endostatin could limit its antitumor activity. Antibodies were detected in the serum and tumor tissues of a patient with multifocal glioblastoma, suggesting that endostatin overexpression could induce a humoral immune response, reducing the effectiveness of viral-mediated endostatin gene therapy when given at high doses. 49 Our data suggest that there is a narrow range for a therapeutic dose of endostatin. However, it is highly likely that the optimum therapeutic dose will be tumor-dependent. Therefore, significant testing will be required in animal tumor models to determine the dose-dependent efficacy. Furthermore, our results indicate that this treatment only delayed tumor incidence because all animals developed tumors even at the optimal doses. This suggests that this treatment would be more suitable as adjuvant therapy or in combination with other antiangiogenic therapies, chemotherapy or radiation.
There is already clinical precedence in designing a clinical trial for an angiogenic inhibitor, INF-a, which has been reported to have a narrow range of antitumor efficacy, that also follows a biphasic U-shaped curve. 46 Therefore, accurate knowledge of the U-shaped parameters of endostatin's antitumor activity and in understanding that the dosing is not linear will allow for better and more effective cancer treatments. Endostatin's U-shaped antitumor activity RM Tjin Tham Sjin et al
